The Patent Finder
IR

Irm LLC

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

17 patents currently held

68 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Sep 2029. from the record

Of the 68 now held by other companies, 28 name Novartis AG as their current owner, and 40 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Sep 2029
Next term end
15
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Peptides and Compositions for Treatment of Joint Damage US 9,301,971
Cited by 20 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Ends Apr 2034 · High confidence
Also notable
N-(HETERO)aryl, 2-(HETERO)ARYL-SUBSTITUTED Acetamides for Use as WNT Signaling Modulators US 9,238,646
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Ends Mar 2030 · High confidence
Also notable
Compounds and Compositions as C-Kit Kinase Inhibitors US 8,569,283
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2032.
Ends Aug 2032 · High confidence

Formerly held, still cited

Notable
Cited by 20 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Ends Jul 2031 · High confidence
Also notable
Cited by 38 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
now held by Novartis AG
Ends Aug 2032 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 11, 2027
    The maintenance fee for Compounds and Compositions as TRK Inhibitors (US 9,102,671) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
  • 1 fee due Mar 24, 2027
    The maintenance fee for Markers Associated with WNT Inhibitors (US 10,422,007) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
  • 1 fee due Apr 6, 2027
    The maintenance fee for Compositions and Methods for Modulating FXR (US 9,150,568) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
  • 2 fees due Jun 1 to 22, 2027 · next Jun 1
  • 1 fee due Jul 19, 2027
    The maintenance fee for N-(HETERO)aryl, 2-(HETERO)ARYL-SUBSTITUTED Acetamides for Use as WNT Signaling Modulators (US 9,238,646) comes due Jul 19, 2027. Unpaid by Jan 19, 2028, it lapses early.
  • 2 fees due Aug 6 to 13, 2027 · next Aug 6
  • 2 fees due Oct 5, 2027

Which patents, and when each one lapses · Pro

Recent changes

  • 3 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,216,964Hedgehog Pathway Modulators
held by Novartis AG
In force
 · High confidence
In forceHigh confidence
US 9,238,646N-(HETERO)aryl, 2-(HETERO)ARYL-SUBSTITUTED Acetamides for Use as WNT Signaling Modulators
held by Novartis AG
In force
 · High confidence
In forceHigh confidence
US 9,469,645Compounds and Compositions for the Treatment of Parasitic Diseases
held by Novartis AG
In force
 · High confidence
In forceHigh confidence
US 9,580,426Compounds That Expand Hematopoietic Stem Cells
In force
 · High confidence
In forceHigh confidence
US 9,365,506Compounds and Compositions as TLR2 Agonists
In force
 · High confidence
In forceHigh confidence
US 9,150,568Compositions and Methods for Modulating FXR
In force
 · High confidence
In forceHigh confidence
US 9,102,671Compounds and Compositions as TRK Inhibitors
In force
 · High confidence
In forceHigh confidence
US 8,569,283Compounds and Compositions as C-Kit Kinase Inhibitors
held by Novartis AG
In force
 · High confidence
In forceHigh confidence
US 9,199,981Compounds and Compositions as C-Kit Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,649,359Peptides and Compositions for Treatment of Joint Damage
In force
 · High confidence
In forceHigh confidence
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
Also on record, not counted in the 17: 68 patents in force now held by others · 133 patents ended · 7 applications pending · 127 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited